FBT - ETF AI Analysis
Top Page
First Trust NYSE Arca Biotechnology Index Fund (FBT)
FBT, the First Trust NYSE Arca Biotechnology Index Fund, earns a solid overall rating largely because it is anchored by strong biotech leaders like Gilead Sciences and Amgen, which show robust financial performance, successful product strategies, and generally favorable long-term outlooks. Other holdings such as Genmab, Corcept Therapeutics, and Illumina add to the fund’s quality through solid growth prospects, though names like NeoGenomics and BeOne Medicines, with profitability challenges, bearish momentum, or valuation concerns, slightly weigh on the rating. The main risk factor is the fund’s concentrated exposure to the biotechnology sector, which can make it more volatile and sensitive to industry-specific setbacks.
FBT vs. SPDR S&P 500 ETF (SPY)
- AUM
- 3.14B
- Region
- North America
- Expense Ratio
- 0.55%
- Beta
- 0.69
- Issuer
- First Trust
- Inception Date
- Jun 19, 2006
- Dividend Yield
- 0.42%
- Asset Class
- Equity
- Index Tracked
- NYSE Arca Biotechnology Index
FBT Summary
FBT is an exchange-traded fund that follows the NYSE Arca Biotechnology Index, focusing on biotech companies within the health care sector. It holds firms working on new drugs, genetic treatments, and other medical innovations. Well-known names in the fund include Biogen and Regeneron, both leaders in developing therapies for serious diseases. Someone might invest in FBT to tap into the potential growth of cutting-edge medical research while spreading their money across many biotech stocks instead of picking just one. A key risk is that biotech shares can be very volatile, so the fund’s value can rise and fall sharply with news and market sentiment.
How much will it cost me?
This ETF has an expense ratio of 0.55%, which means you’ll pay about $5.50 per year for every $1,000 invested. That’s higher than the average ETF because it’s a more specialized, sector-focused fund rather than a broad, low-cost index tracker.
What would affect this ETF?
FBT could benefit if demand for new drugs and medical treatments grows, major biotech companies like Amgen, Regeneron, and Biogen successfully launch breakthrough therapies, and U.S. health care policies support innovation and pricing power. On the negative side, this U.S.-focused biotech fund could be hurt by tighter drug regulations, changes to health care reimbursement, setbacks in clinical trials, or rising interest rates that make investors less willing to back riskier, research-heavy companies.
FBT Top 10 Holdings
FBT is a pure-play U.S. biotech fund, and its story is all about drug pipelines and lab results rather than broad market trends. Genmab and Halozyme are doing much of the heavy lifting, with rising share prices and solid earnings giving the ETF a healthy boost. Established giants like Amgen, Biogen, and Regeneron are steadier anchors, adding incremental gains without much drama. On the flip side, NeoGenomics is lagging as profitability issues weigh on sentiment, while ADMA Biologics’ mixed year shows how volatile smaller biotech names can be.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 GMAB | Genmab | 4.89% | $152.76M | $34.94B | 99.02% | 76Outperform |
 HALO | Halozyme | 3.77% | $117.66M | $14.86B | 102.55% | 73Outperform |
 VCYT | Veracyte | 3.51% | $109.73M | $4.02B | 41.55% | 76Outperform |
 ADMA | ADMA Biologics | 3.50% | $109.30M | $2.56B | -25.28% | 78Outperform |
 ALKS | Alkermes | 3.55% | $110.80M | $7.61B | 47.11% | 80Outperform |
 AMGN | Amgen | 3.57% | $111.48M | $251.94B | 59.59% | 77Outperform |
 BIIB | Biogen | 3.57% | $111.52M | $37.49B | 69.52% | 74Outperform |
 EXEL | Exelixis | 3.68% | $115.04M | $16.93B | 78.20% | 78Outperform |
 REGN | Regeneron | 3.95% | $123.35M | $95.51B | 41.87% | 78Outperform |
 NEO | NeoGenomics | 3.38% | $105.50M | $2.25B | 79.36% | 55Neutral |
FBT Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For FBT, the sentiment is Positive. The current price of 278.55 is above the 20-day moving average (MA) of 268.93, above the 50-day MA of 269.07, and above the 200-day MA of 232.97, indicating a bullish trend. The MACD of 2.95 indicates Negative momentum. The RSI at 61.06 is Neutral, neither overbought nor oversold. The STOCH value of 87.98 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FBT.
FBT Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| FBT | $278.55 | $293.00(5.19% Upside) | $3.14B | 0.55% | 71Outperform |
 IYH | $77.81 | $84.15(8.15% Upside) | $4.63B | 0.37% | 73Outperform |
 FHLC | $88.56 | $98.29(10.99% Upside) | $3.95B | 0.08% | 71Outperform |
 IHI | $54.59 | $60.58(10.97% Upside) | $3.73B | 0.37% | 74Outperform |
 IHE | $107.61 | $128.26(19.19% Upside) | $1.60B | 0.37% | 70Neutral |
 IHF | $59.94 | $69.34(15.68% Upside) | $1.48B | 0.37% | 69Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| FBT | First Trust NYSE Arca Biotechnology Index Fund | 278.55 | 88.45 | 46.53% | |
| IYH | iShares U.S. Healthcare ETF | 77.81 | 17.54 | 29.10% | |
| FHLC | Fidelity MSCI Health Care Index ETF | 88.56 | 19.70 | 28.61% | |
| IHI | iShares U.S. Medical Devices ETF | 54.59 | -6.14 | -10.12% | |
| IHE | iShares U.S. Pharmaceuticals ETF | 107.61 | 32.83 | 43.89% | |
| IHF | iShares U.S. Healthcare Providers ETF | 59.94 | 11.70 | 24.26% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.